Advocacy intelligence hub — real-time data for patient organizations
Atamyo Therapeutics — PHASE1
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Browse all Gamma-sarcoglycan-related limb-girdle muscular dystrophy R5 news →
Nicholas Johnson, MD
Virginia Commonwealth University
📍 Richmond, Virginia
Anne MacGregor, DIPM MFFP
City of London Migraine Clinic
Serge Herson, Prof
Assistance Publique - Hôpitaux de Paris
Amy Huebschmann, MD, MD
University of Colorado, Denver
📍 AURORA, CO
Judith G Regensteiner, PhD
University of Colorado, Denver
View all Gamma-sarcoglycan-related limb-girdle muscular dystrophy R5 specialists →